Posted by Michael Wonder on 03 Mar 2020
Sebela Pharmaceuticals announces FDA approval of Pizensy for oral solution for the treatment of chronic idiopathic constipation in adults
2 March 2020 - Sebela seeks partner to commercialise in the U.S.
Sebela Pharmaceuticals announced today that the U.S. FDA has approved Pizensy (lactitol) for oral solution for the once-daily treatment of chronic idiopathic constipation in adults.
Pizensy is a simple monosaccharide sugar alcohol which exerts an osmotic effect, causing the influx of water into the small intestine leading to a laxative effect.
Pizensy is expected to be available in the U.S. in the second half of 2020. Pizensy is a new chemical entity and is expected to have patent protection until 2037. Sebela intends to commercialise Pizensy in the U.S. with a marketing partner and has received preliminary expressions of interest from a number of interested parties.
